9 Meters Biopharma, Inc.
NMTRQ
$0.00
$0.000.00%
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.00M | 11.01M | 11.18M | 11.15M | 10.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.44M | 42.02M | 40.44M | 40.16M | 37.22M |
| Operating Income | -43.44M | -42.02M | -40.44M | -40.16M | -37.22M |
| Income Before Tax | -46.28M | -43.77M | -41.39M | -45.58M | -42.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.28 | -43.77 | -41.39 | -45.58 | -42.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.28M | -43.77M | -41.39M | -45.58M | -42.70M |
| EBIT | -43.44M | -42.02M | -40.44M | -40.16M | -37.22M |
| EBITDA | -43.43M | -42.01M | -40.43M | -40.15M | -37.22M |
| EPS Basic | -3.52 | -3.38 | -3.20 | -3.55 | -3.35 |
| Normalized Basic EPS | -2.18 | -2.11 | -1.98 | -1.95 | -1.82 |
| EPS Diluted | -3.52 | -3.38 | -3.21 | -3.55 | -3.35 |
| Normalized Diluted EPS | -2.18 | -2.11 | -1.98 | -1.95 | -1.82 |
| Average Basic Shares Outstanding | 52.50M | 51.82M | 51.66M | 51.42M | 50.95M |
| Average Diluted Shares Outstanding | 52.50M | 51.82M | 51.66M | 51.42M | 50.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
